Abxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration ...
German medical giant Fresenius has acquired the remaining 45% stake in mAbxience, completing a full takeover of the biopharmaceutical company, Fresenius said on Thursday. Fresenius, which is based ...
On October 3, 2024, Teva Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar ...
mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to ...
The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, ...
The transaction builds on the successful partnership between Fresenius and mAbxience established in 2022. Full ownership creates a stronger platform to enhance quality and supply resilience, while ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Teva and mAbxience enter into a strategic global ...
mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab ...
Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia A. The candidate is in ...
(RTTNews) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries Ltd. (TEVA) and mAbxience have entered a strategic licensing agreement for a biosimilar candidate ...
mAbxience secures its second 4,000L ABEC Custom Single Run (CSR®) bioreactor to increase manufacturing capacity at its Leon, Spain facility BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a global provider of ...
mAbxience / Key word(s): Joint Venture/Product Launch 04.12.2025 / 09:05 CET/CEST The issuer is solely responsible for the content of this announcement. MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results